NLRP3 and cardiac arrest: Moreover, the delivery of MCC950 led to a significant reduction in the number of CD45high CD11b+ cells (Fig. 6c, d) accompanied by the inhibition of IL-1β and IL-18, suggesting that the intervention of NLRP3 by MCC950 prevents the post-cardiac arrest inflammatory response.